Publicação: Design and synthesis of hybrid compounds as epigenetic modifiers
Carregando...
Data
Orientador
Coorientador
Pós-graduação
Curso de graduação
Título da Revista
ISSN da Revista
Título de Volume
Editor
Tipo
Artigo
Direito de acesso
Resumo
Epigenetic modifiers acting through polypharmacology mechanisms are promising compounds with which to treat several infectious diseases. Histone deacetylase (HDAC) enzymes, mainly class I, and extra-terminal bromodomains (BET) are involved in viral replication and the host response. In the present study, 10 compounds were designed, assisted by molecular docking, to act against HDAC class I and bromodomain-4 (BRD4). All the compounds were synthesized and characterized by analytical methods. Enzymatic assays were performed using HDAC-1,-4, and-11 and BRD4. Compounds (2–10) inhibited both HDAC class I, mainly HDAC-1 and-2, and reduced BRD4 activity. For HDAC-1, the inhibitory effect ranged from 8 to 95%, and for HDAC-2, these values ranged from 10 to 91%. Compounds (2–10) decreased the BRD4 activity by up to 25%. The multi-target effects of these compounds show desirable properties that could help to combat viral infections by acting through epigenetic mechanisms.
Descrição
Palavras-chave
Bromodomain, Drug design, Epigenetic, Histone deacetylase, Hybrid, Molecular hybridization, Polypharmacology, Synthesis
Idioma
Inglês
Como citar
Pharmaceuticals, v. 14, n. 12, 2021.
